Table 2.

Somatic outcomes after six and twelve months of lifestyle intervention in SMI patients. Results of general linear mixed models analyses with adjustment for AP medication side effect

	Waist circumference (N = 238)			BMI (N = 240)			Metabolic syndrome Z-score (N = 115)
	β	95% CI	p-value	β	95% CI	p-value	β	95% CI	p-value
Intervention effecta
at 6 monthsb	−0.15	[− 2.49; 2.19]	.90	0.27	[−0.32; 0.85]	.38	−0.25	[− 0.69;0.18]	.24
at 12 monthsb	−1.03	[−3.42; 1.35]	.39	0.18	[−0.49; 0.86]	.60	−0.30	[−0.66; 0.05]	.09
Group difference (intervention vs control)	2.26	[−3.91; 8.44]	.45	1.47	[−0.17; 3.11]	.08	−0.10	[−0.54; 0.34]	.63
Time effect only
6 months	−0.15	[−1.84; 1.54]	.86	−0.15	[−0.57; 0.27]	.49	0.10	[−0.19; 0.40]	.48
12 months	1.56	[−0.23; 3.34]	.08	−0.26	[−0.77; 0.24]	.31	0.08	[−0.17; 0.33]	.51
AP med. Side effectc
Medium	1.99	[−0.91; 4.90]	.18	0.90	[−0.01; 1.81]	.05	−0.07	[−0.51; 0.36]	.74
High	0.17	[−3.04; 3.38]	.92	0.08	[−1.09; 1.25]	.90	0.40	[0.00; 0.80]	.049

Abbreviations: AP medication side effect: antipsychotic medication side effect on metabolism; CI: confidence interval.

^a control group is reference

^b group x time

^c no AP medication side effect is reference

Bold p-values denote statistical significance at the p < 0.05 level